Stockreport

Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive [Seeking Alpha]

Ocular Therapeutix, Inc.  (OCUL) 
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ocutx.com
PDF AXPAXLI™ leverages proven science and a de-risked trial design, aiming to reduce injection frequency while maintaining vision, targeting a $10B+ market. Phase 1 data [Read more]